Compare FOXF & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOXF | STTK |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 800.6M | 792.9M |
| IPO Year | 2013 | 2020 |
| Metric | FOXF | STTK |
|---|---|---|
| Price | $19.94 | $6.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $30.25 | $10.00 |
| AVG Volume (30 Days) | 378.3K | ★ 727.1K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,467,321,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.27 | N/A |
| 52 Week Low | $13.08 | $1.70 |
| 52 Week High | $28.76 | $8.33 |
| Indicator | FOXF | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 34.66 |
| Support Level | $15.62 | $5.87 |
| Resistance Level | $19.75 | $7.75 |
| Average True Range (ATR) | 0.74 | 0.32 |
| MACD | -0.25 | -0.16 |
| Stochastic Oscillator | 19.34 | 6.10 |
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World. The company operates in three segments: Powered Vehicles Group, Aftermarket Applications Group, and Specialty Sports Group, of which it derives maximum revenue from Specialty Sports Group segment.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.